ASCO: Aggressive Treatment Common in Terminal CA Patients

Share this content:
ASCO: Aggressive Treatment Common in Terminal CA Patients
ASCO: Aggressive Treatment Common in Terminal CA Patients

TUESDAY, June 7, 2016 (HealthDay News) -- Three-quarters of young or middle-aged Americans with terminal cancer receive aggressive treatment during the last month of their lives, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 3 to 7 in Chicago.

Ronald Chen, M.D., M.P.H., an associate professor of radiation oncology at the University of North Carolina in Chapel Hill, and colleagues reviewed claims data for more than 28,000 terminally ill cancer patients younger than 65 who died between 2007 and 2014. The patients lived across 14 different states, and had been diagnosed with advanced lung, colorectal, breast, pancreatic, or prostate cancer. The researchers defined aggressive care as chemotherapy, radiation therapy, hospital/emergency room treatment, admission to an intensive care unit (ICU), or dying in a hospital.

The investigators found that between 71 and 76 percent of patients received some form of aggressive care at the end of life, depending on their type of cancer. Chemotherapy use ranged from 24 to 33 percent; rates of radiation therapy ranged between 6 and 21 percent; between 25 and 31 percent of patients underwent an invasive procedure such as a biopsy or surgery; and about 16 to 21 percent of patients were admitted to the ICU. One-third died in a hospital, while fewer than one in five used hospice care.

"Additional efforts are critically needed to improve end-of-life care for patients with terminal disease, to ensure that the care provided meets the goals and preferences of patients and their families," Chen told HealthDay.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »